[Edaily Reporter Shin Ha-yeon] On the 19th, Hana Securities projected that #LaserOptic would enter a phase of earnings recovery this year driven by new product launches, followed by a growth phase starting next year as the U.S. market normalizes. The firm did not provide a specific investment rating or target price.

Laser Optic is a company that develops and sells laser medical devices for cosmetic skin treatments and medical conditions. Last year, cosmetic skin treatment devices and medical condition treatment devices accounted for 81% and 9% of total revenue, respectively. Its main products include the PicoLo, HELIOS, LOTUS, SCULPIO, and PALLAS series.

Hana Securities identified the new product “SCULPIO” as the key driver of this year’s earnings recovery. SCULPIO is an upgraded version of the existing PicoLo series of scar treatment devices, combining pico-laser technology with lifting functions.

Kim Da-hye, an analyst at Hana Securities, stated, “We expect revenue and margins to improve as sales of consumables expand due to the growth of SCULPIO, a cosmetic medical device launched in March 2025.” She added, “Given SCULPIO’s high equipment price and the inclusion of a handpiece with a shot-count feature, its growth will enable an expansion in high-margin consumable sales.”

She continued, “Consumer response has been positive, as a single treatment provides both pico-laser and lifting effects,” explaining, “Sculpio sales are gradually increasing, centered on local dermatology clinics, which are the company’s main sales channels.”

He projected that the normalization of sales for medical devices used to treat medical conditions starting next year will serve as a catalyst for full-scale growth. In particular, he highlighted the potential for the resumption of U.S. sales of “PALLAS PREMIUM,” a high-margin product.

Analyst Kim stated, “Sales of the high-margin therapeutic medical device PALLAS PREMIUM in the U.S., which had been suspended due to litigation, are set to resume next year and will drive a recovery in earnings,” adding, “An announcement is scheduled for next year stating that competitor product names will be removed from the insurance code description for PALLAS PREMIUM, making the resumption of sales likely.”

Sales in North America plummeted from 5.1 billion won in 2024 to 1.3 billion won in 2025 due to the suspension of sales for this product. Hana Securities predicted that, given the high selling price of PALLAS PREMIUM overseas, a significant recovery in earnings would be possible once sales resume.

The company assesses that this year, the new products VasCura and Sculpio will play a role in filling the export gap. VasCura, a medical device for treating vascular skin conditions launched in June of this year, is used to treat various vascular skin conditions such as port-wine stains, hemangiomas, and erythema.

Analyst Kim predicted, “This year, sales of the VasCura 589—a device for treating vascular skin conditions newly launched in June—along with last year’s new Sculpio equipment and consumables, will fill the export gap left by PALLAS PREMIUM, and full-scale growth is expected to resume starting next year.”

He added, “In the aesthetic medical laser market, where new product launches are slow due to the oligopoly of global companies, LaserOptic’s positioning as a domestic EBD company with proprietary technology—introducing new products that reflect trends in consumables and skin tightening—and a diverse portfolio of laser equipment is highly attractive.”